You are here: Home » Companies » News
Business Standard

VAV Life Sciences unit to reach 40% of global mRNA lipid capacity next yr

Firm expanding mRNA lipids capacity 10-fold, overall plant capacity by 6 times by June

Vaccine | manufacturing

Sohini Das  |  Mumbai 

Biocon Biologics

Mumbai-based firm VAV Life Sciences is expanding its mRNA lipids capacity 10-fold by June 2022. It will then account for 40 percent of the total global capacity for m-RNA lipids, a critical component that goes into making mRNA vaccines and also various mRNA tech based therapeutic products which lends permeability and stability to the biologic product.

Apart from VAV, there are only three more in the world who make mRNA lipids. US-based Avanti Polar Lipids, Germany’s Lipoid and Japan’s NOF Corporation and VAV together now make 1,000 kg a year. However, the projected demand for mRNA lipids would be 2,500 kg per year by 2025-26.

VAV Life Sciences is investing Rs 15 crore (through its subsidiary VAV Lipids) or so to expand the capacity at the Ratnagiri plant overall by 6 times. Of this, the mRNA lipids capacity for vaccines would be expanded by 10 times the current production to 1,500 kg a year. The company makes 30-40 types of other lipids too, some of which are nutritional.

“This is in preparation for the future. At present, mRNA products are only vaccines, and there are no commercially approved products based on the mRNA platform technology. However, we expect a rise in demand for mRNA lipids in the future,” Arun Kedia, Managing Director VAV said. This would not only be sufficient for the Indian requirement, but also cater to 40 per cent of the global demand, Kedia said, adding that they target to be the largest mRNA lipids company in the world. Going forward, Kedia plans to have plants in Europe to be closer to their customers. VAV exports almost 80 per cent of its products primarily to North America, Europe, and Asia.

He said that since the past five years or so, they have been supplying the mRNA lipids to several companies, however, that was primarily for research purposes.


VAV is the only Indian and fourth global producer of highly purified lipids that are approved for use in novel drug delivery systems (NDDS).

The new capacity which would be operational from June 2022 will boost VAV’s sales by about 3.5 times to reach RS 45 crore ($6 million) by 2023.

According to the company, the project is funded by internal accruals and EXIM-bank debt. Kedia, who is a chemical engineer by training, has bootstrapped the start-up so far, and has no external investor on board. “Our growth has been organic funded by internal accruals,” he said.

VAV Lifesciences Private Limited is a nanotechnology research-based biopharmaceuticals company. The company produces ingredients used in the pharmaceutical, nutraceutical, and healthcare and personal care industries. VAV’s product portfolio includes plant phospholipids (LECIVA), Animal phospholipids (LIPOVA), synthetic phospholipids, and neutral lipids. The other products include APIs and specialty proteins.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 24 2021. 18:40 IST